Delivery Order SPE2DB20D2104-SPE2DB25FNABL
- Not listed
- The Defense Logistics Agency awarded a $3,561.92 delivery order to AmerisourceBergen Drug Corp for Restasis 0.05% Eye Emulsion (30-count) on September 12, 2025, with an ultimate completion date of September 15, 2025. This competitive award, issued under firm fixed-price terms with no set-aside designation, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical supply...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on November 8, 2024, for the supply of Restasis 0.05% Eye Emulsion (60-count units) with a ceiling value of $2,822.04. This is a firm fixed-price delivery order with an ultimate completion date of November 12, 2024, and represents a competitively awarded contract with no set-aside designation. The award was made to AmerisourceBergen's Corporate Office division, headquartered in...
- The Defense Logistics Agency awarded a delivery order valued at $6,110.43 to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Restasis 0.05% Eye Emulsion in 30-unit quantities. This is a firm fixed price delivery order with an ultimate completion date of September 12, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a non-competitive procurement under AmerisourceBergen's existing indefinite delivery contract...
- The Defense Logistics Agency awarded a $12,777.96 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Restasis 0.05% Eye Emulsion in 60-count units. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive procurement. Performance will be completed by July 29, 2025, with work performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order valued at $14,980.58 to AmerisourceBergen Drug Corp for the supply of Restasis 0.05% Eye Emulsion (60-count units) on September 4, 2025, with an ultimate completion date of September 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a continuation of the vendor's extensive pharmaceutical supply relationship with the federal government. The product will be delivered to...
- The Defense Logistics Agency awarded a $3,018.16 delivery order to AmerisourceBergen Drug Corp for RESTASIS 0.05% Eye Emulsion (30-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $28,637.24 by the Defense Logistics Agency (DLA) on July 25, 2025, for the supply of Restasis 0.05% Eye Emulsion in 60-count units. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 28, 2025. The contract will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $2,570.71 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Restasis 0.05% Eye Emulsion (30-count units) on August 19, 2025, with an ultimate completion date of August 20, 2025. The contract, which carries no set-aside designation, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $1,293.44 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Restasis 0.05% Eye Emulsion (60-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This non-set-aside contract was competitively awarded and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Restasis 0.05% eye emulsion (30 count) at a firm fixed price of $1,117.80. The contract, which is non-set-aside and competitively awarded, has an ultimate completion date of August 4, 2025, with performance to be completed at AmerisourceBergen's Conshohocken, Pennsylvania facility. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FNABLDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,916.15 to AmerisourceBergen Drug Corp for the supply of Restasis 0.05% Eye Emulsion (60 units) on September 10, 2025, with completion scheduled for September 11, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime contract vehicle extending through December 2026 that enables the company to supply comprehensive pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that serves as a critical federal medical procurement vendor for the Defense Logistics Agency and other government healthcare systems, including the Defense Health Agency and U.S. Coast Guard. The company's extensive federal contract portfolio demonstrates its capability to fulfill diverse pharmaceutical needs across multiple therapeutic domains through competitively awarded delivery orders with firm fixed pricing. This award of Restasis—an ophthalmic pharmaceutical—reflects the company's ongoing role in supplying specialized brand-name medications to support military and federal healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.9k | 9/10/25 |